A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

计划入组 8 人 · 首次发布于 2022 年 1 月 20 日

Satralizumab in Aneurysmal Subarachnoid Hemorrhage

首次发布于 2023 年 2 月 14 日

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

计划入组 95 人 · 首次发布于 2014 年 2 月 27 日

Satralizumab(Enspryng)

Rx

Spartalizumab

Sytalizumab

FDA Grants Priority Review to Roche's Enspryng as First At-Home Subcutaneous Therapy for Thyroid Eye Disease

FDA Blocks Approval of AstraZeneca's Ultomiris for Neuromyelitis Optica Spectrum Disorder

FDA Grants Priority Review to Roche's Enspryng for MOGAD, With Decision Due January 2027